PIRS - Pieris Pharma Total Debt to Capital

Pieris Pharmaceuticals (PIRS) specializes in developing innovative protein anticalins to combat pulmonary and cancer pathologies. This price chart illustrates low capital expenditures driven by German R&D and US manufacturing outsourcing, with the indicator standing at 0.11. The company is currently undergoing a rigorous reorganization following the collapse of deals, seeking to find a buyer for its patents or merge with another player.

For the biotech business of Pieris Pharmaceuticals (PIRS), which relies on licensing payments and partner royalties, maintaining a low debt-to-equity ratio is critical. By analyzing the leverage ratio—total debt to equity—an investor assesses the proportion of external financing within the asset structure, which determines the company's ability to survive periods without upfront payments without risking bankruptcy.